Seres Therapeutics (NASDAQ:MCRB) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a report issued on Wednesday.

According to Zacks, “Seres Therapeutics, Inc. offers microbiome therapeutics platform. It is focused on developing Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome. Seres Therapeutics, Inc. is headquartered in Cambridge, Massachusetts. “

MCRB has been the subject of a number of other reports. ValuEngine lowered shares of Seres Therapeutics from a “hold” rating to a “sell” rating in a report on Thursday, September 21st. Citigroup assumed coverage on shares of Seres Therapeutics in a research report on Thursday, October 12th. They set a “positive” rating and a $19.00 price objective on the stock. Cowen reissued a “buy” rating on shares of Seres Therapeutics in a research report on Monday, October 2nd. Oppenheimer assumed coverage on shares of Seres Therapeutics in a research report on Thursday, October 12th. They set an “outperform” rating and a $19.00 price objective on the stock. Finally, Seaport Global Securities reissued a “buy” rating and set a $20.00 price objective on shares of Seres Therapeutics in a research report on Friday, October 6th. Two analysts have rated the stock with a sell rating, one has issued a hold rating and nine have issued a buy rating to the company. The company currently has an average rating of “Buy” and a consensus price target of $18.00.

Shares of Seres Therapeutics (NASDAQ:MCRB) opened at $10.02 on Wednesday. Seres Therapeutics has a 1-year low of $8.85 and a 1-year high of $17.42. The company has a current ratio of 6.53, a quick ratio of 6.53 and a debt-to-equity ratio of 0.11. The company has a market cap of $406.11 and a price-to-earnings ratio of -4.73.

Seres Therapeutics (NASDAQ:MCRB) last posted its quarterly earnings results on Wednesday, November 8th. The biotechnology company reported ($0.17) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.39) by $0.22. Seres Therapeutics had a negative net margin of 267.15% and a negative return on equity of 82.11%. The company had revenue of $23.00 million during the quarter, compared to analyst estimates of $17.29 million. During the same period in the prior year, the business posted ($0.46) EPS. The firm’s revenue was up 76.9% compared to the same quarter last year. equities analysts anticipate that Seres Therapeutics will post -2.33 earnings per share for the current fiscal year.

A number of institutional investors have recently modified their holdings of the business. Vanguard Group Inc. grew its position in shares of Seres Therapeutics by 1.2% in the 2nd quarter. Vanguard Group Inc. now owns 1,585,026 shares of the biotechnology company’s stock worth $17,911,000 after buying an additional 19,363 shares during the period. Ark Investment Management LLC grew its position in shares of Seres Therapeutics by 21.5% in the 2nd quarter. Ark Investment Management LLC now owns 765,191 shares of the biotechnology company’s stock worth $8,647,000 after buying an additional 135,276 shares during the period. JPMorgan Chase & Co. grew its position in shares of Seres Therapeutics by 39.9% in the 3rd quarter. JPMorgan Chase & Co. now owns 373,334 shares of the biotechnology company’s stock worth $6,160,000 after buying an additional 106,479 shares during the period. State Street Corp grew its position in shares of Seres Therapeutics by 12.0% in the 2nd quarter. State Street Corp now owns 321,699 shares of the biotechnology company’s stock worth $3,637,000 after buying an additional 34,393 shares during the period. Finally, Northern Trust Corp grew its position in shares of Seres Therapeutics by 16.2% in the 2nd quarter. Northern Trust Corp now owns 235,766 shares of the biotechnology company’s stock worth $2,664,000 after buying an additional 32,875 shares during the period. 75.94% of the stock is currently owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY NOTICE: “Seres Therapeutics (MCRB) Downgraded by Zacks Investment Research to “Sell”” was originally reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this news story on another site, it was illegally copied and republished in violation of international copyright law. The legal version of this news story can be viewed at https://www.thecerbatgem.com/2018/01/10/seres-therapeutics-mcrb-downgraded-by-zacks-investment-research-to-sell.html.

About Seres Therapeutics

Seres Therapeutics, Inc is a microbiome therapeutics platform company. The Company is engaged in developing a class of biological drugs, which is referred as Ecobiotic microbiome therapeutics. The Company’s drugs are designed to restore health by repairing the function of a dysbiotic microbiome. The Company is focused on implementing its microbiome therapeutics platform to develop Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome.

Get a free copy of the Zacks research report on Seres Therapeutics (MCRB)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Seres Therapeutics (NASDAQ:MCRB)

Receive News & Stock Ratings for Seres Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seres Therapeutics and related stocks with our FREE daily email newsletter.